CME Series | Advances in Clinical Pharmacology of Infectious Diseases
This module offers a focused overview of optimal antiviral therapy - HIV PEP, monoclonal antibodies in pediatric infectious diseases, and future directions in HCV. Topics include drug–drug interactions, pharmacokinetics and pharmacodynamics, dosing in under-represented populations, post-marketing safety, and regulatory considerations.
What Will Set You Apart?
After following this educational series, participants will:
- Summarize key guidelines and challenges in HIV PEP
- Describe the role of monoclonal antibodies in pediatric infectious diseases
- Outline emerging treatment directions for HCV
Is This Program for You?
This program is designed for clinical pharmacologists, pharmacists, clinicians, researchers, postgraduate students, and others engaged in the clinical pharmacology of antiviral therapy.
What Will You Cover in This Module?
- HIV PEP in Clinical Practice
- Monoclonal Antibodies in Pediatric Infectious Diseases
- What Is Next for HCV?
Login to access this course
For full access to this course's material, you first need to log in or create an account.
EACCME Accreditation Statement
The CME Series | Advances in Clinical Pharmacology of Infectious Diseases made available on https://academicmedicaleducation.com/e-learning and organized by Virology Education & Academic Medical Education is accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) to provide the following CME activity for medical specialists.
Only those e-learning materials that are displayed on the UEMS-EACCME® website have formally been accredited.
Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at https://edhub.ama-assn.org/pages/applications.